{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(4)"],"submitter":["Vial JP"],"pubmed_abstract":["The assessment of minimal residual disease (MRD) is increasingly considered to monitor response to therapy in hematological malignancies. In acute myeloblastic leukemia (AML), molecular MRD (mMRD) is possible for about half the patients while multiparameter flow cytometry (MFC) is more broadly available. However, MFC analysis strategies are highly operator-dependent. Recently, new tools have been designed for unsupervised MFC analysis, segregating cell-clusters with the same immunophenotypic characteristics. Here, the Flow-Self-Organizing-Maps (FlowSOM) tool was applied to assess MFC-MRD in 96 bone marrow (BM) follow-up (FU) time-points from 40 AML patients with available mMRD. A reference FlowSOM display was built from 19 healthy/normal BM samples (NBM), then simultaneously compared to th"],"journal":["Cancers"],"pagination":["629"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7914957"],"repository":["biostudies-literature"],"pubmed_title":["Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia."],"pmcid":["PMC7914957"],"pubmed_authors":["Vergez F","Pigneux A","Leguay T","Vial JP","Bidet A","Lechevalier N","Lacombe F","Bene MC","Dumas PY"],"additional_accession":[]},"is_claimable":false,"name":"Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia.","description":"The assessment of minimal residual disease (MRD) is increasingly considered to monitor response to therapy in hematological malignancies. In acute myeloblastic leukemia (AML), molecular MRD (mMRD) is possible for about half the patients while multiparameter flow cytometry (MFC) is more broadly available. However, MFC analysis strategies are highly operator-dependent. Recently, new tools have been designed for unsupervised MFC analysis, segregating cell-clusters with the same immunophenotypic characteristics. Here, the Flow-Self-Organizing-Maps (FlowSOM) tool was applied to assess MFC-MRD in 96 bone marrow (BM) follow-up (FU) time-points from 40 AML patients with available mMRD. A reference FlowSOM display was built from 19 healthy/normal BM samples (NBM), then simultaneously compared to th","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2025-04-04T19:15:11.658Z","creation":"2025-04-04T19:15:11.658Z"},"accession":"S-EPMC7914957","cross_references":{"pubmed":["33562525"],"doi":["10.3390/cancers13040629"]}}